Immunotherapy in gastric carcinoma: Current status and future perspectives

Lionel Kankeu Fonkoua, Nelson S. Yee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Gastric carcinoma (GC) is a globally prevalent malignant disease and it is associated with a high mortality rate. Recent advances have been made in development of immunotherapies that aim at modulating the patients’ immune system and the tumor-associated microenvironment. Methods: The field of cancer immunology that is pertinent to GC was provided. The basis for immunotherapeutic approaches to advanced GC was reviewed. Results of the clinical studies obtained from the literature in PubMed as well as the ongoing clinical trials as listed in www.ClinicalTrials.gov were described and discussed. Results: One major approach of immunotherapy in GC employs therapeutic antibodies that target mitogenic signaling pathways, angiogenesis, and immune checkpoint molecules. Clinical studies have demonstrated efficacy using trastuzumab and ramucirumab that target human epidermal growth factor receptor 2 and vascular endothelial growth factor receptor 2, respectively. Other approaches involve adoptive transfer of cellular mediators of immune response as well as tumor cell-based vaccines. Conclusion: The success of antibody-based therapy has been limited by genetic heterogeneity of GC and plasticity of the molecular targets. Immunotherapeutic approach as monotherapy in GC has not produced the desirable clinical outcomes. Novel strategies that target multiple driver mutations of gastric tumorigenesis and combination of immuno-, chemo-, and radiation therapy will hopefully create new opportunity to improve the treatment outcomes. An integrative approach using molecular tumor profiling and targeted immunotherapeutics is expected to make a positive impact towards the goal of precision therapy in this highly lethal malignancy.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalClinical Cancer Drugs
Volume2
Issue number2
StatePublished - Dec 1 2015

Fingerprint

Immunotherapy
Stomach
Carcinoma
Neoplasms
Vascular Endothelial Growth Factor Receptor-2
Tumor Microenvironment
Genetic Heterogeneity
Adoptive Transfer
Antibodies
Allergy and Immunology
PubMed
Cellular Immunity
Immune System
Carcinogenesis
Radiotherapy
Therapeutics
Vaccines
Clinical Trials
Mutation
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Cancer Research

Cite this

@article{a729178251214cdfb2839efd63fa8612,
title = "Immunotherapy in gastric carcinoma: Current status and future perspectives",
abstract = "Background: Gastric carcinoma (GC) is a globally prevalent malignant disease and it is associated with a high mortality rate. Recent advances have been made in development of immunotherapies that aim at modulating the patients’ immune system and the tumor-associated microenvironment. Methods: The field of cancer immunology that is pertinent to GC was provided. The basis for immunotherapeutic approaches to advanced GC was reviewed. Results of the clinical studies obtained from the literature in PubMed as well as the ongoing clinical trials as listed in www.ClinicalTrials.gov were described and discussed. Results: One major approach of immunotherapy in GC employs therapeutic antibodies that target mitogenic signaling pathways, angiogenesis, and immune checkpoint molecules. Clinical studies have demonstrated efficacy using trastuzumab and ramucirumab that target human epidermal growth factor receptor 2 and vascular endothelial growth factor receptor 2, respectively. Other approaches involve adoptive transfer of cellular mediators of immune response as well as tumor cell-based vaccines. Conclusion: The success of antibody-based therapy has been limited by genetic heterogeneity of GC and plasticity of the molecular targets. Immunotherapeutic approach as monotherapy in GC has not produced the desirable clinical outcomes. Novel strategies that target multiple driver mutations of gastric tumorigenesis and combination of immuno-, chemo-, and radiation therapy will hopefully create new opportunity to improve the treatment outcomes. An integrative approach using molecular tumor profiling and targeted immunotherapeutics is expected to make a positive impact towards the goal of precision therapy in this highly lethal malignancy.",
author = "Fonkoua, {Lionel Kankeu} and Yee, {Nelson S.}",
year = "2015",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
pages = "91--99",
journal = "Clinical Cancer Drugs",
issn = "2212-697X",
publisher = "Bentham Science Publishers",
number = "2",

}

Immunotherapy in gastric carcinoma : Current status and future perspectives. / Fonkoua, Lionel Kankeu; Yee, Nelson S.

In: Clinical Cancer Drugs, Vol. 2, No. 2, 01.12.2015, p. 91-99.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunotherapy in gastric carcinoma

T2 - Current status and future perspectives

AU - Fonkoua, Lionel Kankeu

AU - Yee, Nelson S.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Gastric carcinoma (GC) is a globally prevalent malignant disease and it is associated with a high mortality rate. Recent advances have been made in development of immunotherapies that aim at modulating the patients’ immune system and the tumor-associated microenvironment. Methods: The field of cancer immunology that is pertinent to GC was provided. The basis for immunotherapeutic approaches to advanced GC was reviewed. Results of the clinical studies obtained from the literature in PubMed as well as the ongoing clinical trials as listed in www.ClinicalTrials.gov were described and discussed. Results: One major approach of immunotherapy in GC employs therapeutic antibodies that target mitogenic signaling pathways, angiogenesis, and immune checkpoint molecules. Clinical studies have demonstrated efficacy using trastuzumab and ramucirumab that target human epidermal growth factor receptor 2 and vascular endothelial growth factor receptor 2, respectively. Other approaches involve adoptive transfer of cellular mediators of immune response as well as tumor cell-based vaccines. Conclusion: The success of antibody-based therapy has been limited by genetic heterogeneity of GC and plasticity of the molecular targets. Immunotherapeutic approach as monotherapy in GC has not produced the desirable clinical outcomes. Novel strategies that target multiple driver mutations of gastric tumorigenesis and combination of immuno-, chemo-, and radiation therapy will hopefully create new opportunity to improve the treatment outcomes. An integrative approach using molecular tumor profiling and targeted immunotherapeutics is expected to make a positive impact towards the goal of precision therapy in this highly lethal malignancy.

AB - Background: Gastric carcinoma (GC) is a globally prevalent malignant disease and it is associated with a high mortality rate. Recent advances have been made in development of immunotherapies that aim at modulating the patients’ immune system and the tumor-associated microenvironment. Methods: The field of cancer immunology that is pertinent to GC was provided. The basis for immunotherapeutic approaches to advanced GC was reviewed. Results of the clinical studies obtained from the literature in PubMed as well as the ongoing clinical trials as listed in www.ClinicalTrials.gov were described and discussed. Results: One major approach of immunotherapy in GC employs therapeutic antibodies that target mitogenic signaling pathways, angiogenesis, and immune checkpoint molecules. Clinical studies have demonstrated efficacy using trastuzumab and ramucirumab that target human epidermal growth factor receptor 2 and vascular endothelial growth factor receptor 2, respectively. Other approaches involve adoptive transfer of cellular mediators of immune response as well as tumor cell-based vaccines. Conclusion: The success of antibody-based therapy has been limited by genetic heterogeneity of GC and plasticity of the molecular targets. Immunotherapeutic approach as monotherapy in GC has not produced the desirable clinical outcomes. Novel strategies that target multiple driver mutations of gastric tumorigenesis and combination of immuno-, chemo-, and radiation therapy will hopefully create new opportunity to improve the treatment outcomes. An integrative approach using molecular tumor profiling and targeted immunotherapeutics is expected to make a positive impact towards the goal of precision therapy in this highly lethal malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85042572259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042572259&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85042572259

VL - 2

SP - 91

EP - 99

JO - Clinical Cancer Drugs

JF - Clinical Cancer Drugs

SN - 2212-697X

IS - 2

ER -